AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

In terms of PFS, the way this study is powered ... how do you foresee the competitive landscape for third-line DLBCL evolving in 2025 and beyond? And how might that differ from '24?

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma ... free survival (PFS), with overall survival ...

ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the ...

Patients with advanced disease or symptomatic disease have a 5-year PFS around 50%. Secondary cutaneous involvement is uncommon in DLBCL, although it has been observed in up to 20% of cases in some ...

Stock price fell 1.9% in premarket, nearing the 52-week low. Promising trial results in DLBCL and indolent lymphomas. Continued focus on expanding ZENLANTA market presence. ADC Therapeutics ...

Share-based compensation expense represents the cost of equity awards issued to our directors, management and employees. The fair value of awards is computed at the time the award is granted and ...

- Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income. - Net Loss Reduction: 71.5% year-over-year improvement. - China: Approved for first-line treatment ...

SUZHOU, China, March 27, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today reported 2024 annual ...